Sex differences in cocaine-dependent individuals' response to disulfiram treatment

Yale University School of Medicine, VA Connecticut Health Care System, West Haven, USA.
Addictive Behaviors (Impact Factor: 2.44). 09/2004; 29(6):1123-8. DOI: 10.1016/j.addbeh.2004.03.004
Source: PubMed

ABSTRACT The objective of this study is to evaluate differential response to disulfiram treatment of cocaine dependence by sex. Sex by treatment interactions from two pooled randomized clinical trials involving 191 cocaine-dependent subjects (36% female) were evaluated. Primary outcomes were days of abstinence and percentage of drug-free urine specimens. Significant sex by treatment interactions were found, where men treated with disulfiram had better outcomes than those who were not. Women had an intermediate outcome regardless of whether they received disulfiram. Sex differences in response to disulfiram treatment have important clinical and theoretical implications. Reasons for this apparent sex-based response are not clear, but possible mechanisms worthy of greater study include differences in alcohol use by sex as well as differences in dopamine-mediated responses to cocaine and disulfiram.

  • [Show abstract] [Hide abstract]
    ABSTRACT: There has been growing evidence in recent years of the importance of gender specific issues in the addiction field. This paper explores specific problems and including specific health consequences faced by women who drink or use drugs. We describe helpful screening tools that can be used in the primary care setting and offer an understanding of some of the barriers preventing women from seeking help. This article also provides guidance on the best pharmacotherapy and psychological interventions that can be used to help women recover from their addiction.
    CNS spectrums 02/2011; 16(2):37-47. DOI:10.1017/S1092852912000168 · 1.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions.
    Neuropharmacology 04/2014; 87. DOI:10.1016/j.neuropharm.2014.04.002 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite extensive research on gender differences in addiction, there are relatively few published reports comparing treatment outcomes for women versus men based on evidence-based treatments evaluated in randomized clinical trials. An aggregate sample comprised of data from five randomized clinical trials of treatment for cocaine dependence (N=434) was evaluated for gender differences in clinical outcomes. Secondary analyses compared gender differences in outcome by medication condition (disulfiram versus no medication) and across multiple behavioral treatment conditions. Women, compared with men, had poorer treatment outcomes on multiple measures of cocaine use during treatment and at post-treatment follow-up. These results appear to be primarily accounted for by disulfiram being less effective in women compared with men. There was no evidence of meaningful gender differences in outcome as a function of the behavioral therapies evaluated. These findings suggest that women and men may benefit to similar degrees from some empirically validated behavioral treatments for addiction. Conversely, some addiction pharmacotherapies, such as disulfiram, may be associated with poorer outcomes among women relative to men and point to the need for careful assessment of pharmacological treatments in both sexes prior to widespread clinical implementation. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    Drug and Alcohol Dependence 10/2014; 145C:156-167. DOI:10.1016/j.drugalcdep.2014.10.007 · 3.28 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014